PLC Systems to Present at the ROTH Conference
Share:
FRANKLIN, Mass., Feb. 14 - PLC Systems Inc. (AMEX:PLC) today announced that it will participate in the ROTH 20th Annual OC Growth Stock Conference on February 18-21, 2008 at the Ritz Carlton Laguna Niguel in Dana Point, CA. PLC is scheduled to present on February 20th beginning at 3:30 pm local time. Presenting for the company will be Mark R. Tauscher, President and CEO.
A webcast of the presentation will be available at the company's website (www.plcmed.com) or by following this link: http://wsw.com/webcast/roth16/plc/.
The webcast will be archived on the company's website for 30 days following completion of the event.
About PLC Systems Inc.
PLC Systems Inc. is a medical technology company specializing in innovative technologies for the cardiac and vascular markets. Headquartered in Franklin, Mass., PLC pioneered the CO2 Heart Laser System, which cardiac surgeons use to perform CO2 transmyocardial revascularization (TMR) to alleviate symptoms of severe angina. CO2 TMR offers a treatment option for angina patients who suffer from severe coronary artery disease. The CO2 Heart Laser is the world's first TMR angina relief device cleared for commercial distribution by both the U.S. Food and Drug Administration and Japanese Ministry of Health, Labor and Welfare, and to obtain a CE Mark for European distribution.
The company has completed a pilot clinical safety study of its RenalGuard Therapy(TM) and RenalGuard System. In late 2007, the company received its CE Mark Certificate for RenalGuard System. RenalGuard Therapy is designed to reduce the toxic effects that contrast media can have on the kidneys. This therapy is based on the theory that creating and maintaining a high urine output is beneficial to patients undergoing imaging procedures where contrast agents are used. The real-time measurement and matched fluid replacement design of the RenalGuard System is intended to ensure that a high urine flow is maintained before, during and after these procedures. This should allow the body to rapidly eliminate contrast, reducing its toxic effects. The RenalGuard System, with its matched fluid replacement capability, is intended to minimize the risk of over- or under-hydration.
Additional company information can be found at www.plcmed.com.
FCMN Contact: mtconway@worldnet.att.net
Source: PLC Systems Inc.
CONTACT: Mary T. Conway of Conway Communications for PLC Systems Inc.,
+1-617-244-9682, mtconway@att.net
Web site: www.plcmed.com/
http://wsw.com/webcast/roth16/plc
http://www.roth.com/main/page.aspx?PageID=7000
